Evidence map›Paper›PMID 40985107›Full record

ArticleFuture medicinal chemistry2025

Design and evaluation of 2-(4-((2-(2-((2,6-dichloro-3-methylphenyl)amino)benzoyl)hydrazineylidene)methyl)phenoxy)acetic acid as a dual anti-inflammatory and anti-diabetic agent.

Mohamed K Elgohary, Mahmoud S Elkotamy, Mahmoud Abdelrahman Alkabbani, Ahmed Mohamed El-Khatib, Aya Mohamed Ahmed Ibrahim, Ali Mohamed Alshabi, Abdulrahman A Almehizia, Ahmed M Naglah, Hazem A Ghabbour, Hatem A Abdel-Aziz

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Future medicinal chemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Mohamed K ElgoharyPharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian-Russian University, Badr City, Cairo, Egypt.ORCID 0000-0002-8269-9526
Mahmoud S ElkotamyPharmaceutical Chemistry Department, Faculty of Pharmacy, Egyptian-Russian University, Badr City, Cairo, Egypt.
Mahmoud Abdelrahman AlkabbaniPharmacology and Toxicology Department, Faculty of Pharmacy, Egyptian-Russian University, Badr City, Cairo, Egypt.
Ahmed Mohamed El-KhatibMicrobiology and Immunology Department, Faculty of Pharmacy, Egyptian Russian University, Cairo, Egypt.
Aya Mohamed Ahmed IbrahimDepartment of Biochemistry, Faculty of Pharmacy, Egyptian Russian University, Badr City, Cairo, Egypt.
Ali Mohamed AlshabiDepartment of Clinical Pharmacy, College of Pharmacy, Najran University, Najran, Saudi Arabia.
Abdulrahman A AlmehiziaDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Ahmed M NaglahDepartment of Pharmaceutical Chemistry, College of Pharmacy, King Saud University, Riyadh, Saudi Arabia.
Hazem A GhabbourSchool of Health and Biomedical Sciences, RMIT University, Melbourne, Australia.
Hatem A Abdel-AzizApplied Organic Chemistry Department, National Research Center, Cairo, Egypt.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aimsThis study aimed to design, synthesize, and evaluate a novel meclofenamic acid derivative (7) for its potential as a dual-target therapeutic agent with anti-inflammatory, antidiabetic, antioxidant, and anticancer activities. MATERIALS &

methodsCompound 7 was synthesized and subjected to in vitro, in vivo, and in silico evaluations. Anti-inflammatory activity was assessed using acute and chronic models, including IL-6 and NF-κB quantification and histopathology. Antidiabetic potential was evaluated through α-glucosidase inhibition, glucose tolerance, and alloxan-induced diabetic models. Antioxidant activity was tested against ascorbic acid, while cytotoxicity was assessed on MCF-7, T24, and A-549 cell lines. Molecular docking, ADME profiling, and pathway analyses were performed to predict drug-likeness and target interactions.

resultsCompound 7 exhibited potent anti-inflammatory activity (IC

conclusionsComputational and experimental findings suggest that compound 7 exhibits favorable drug-like properties and holds promise as a multi-target therapeutic candidate.

Indexed as

Anti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalAntineoplastic AgentsAntioxidantsDiabetes Mellitus, ExperimentalDrug DesignHypoglycemic Agentsalpha-GlucosidasesAnimalsCell Line, TumorCell ProliferationGlycoside Hydrolase InhibitorsHumansInterleukin-6MaleMolecular Docking Simulationalpha-GlucosidasesAnti-Inflammatory AgentsAnti-Inflammatory Agents, Non-SteroidalAntineoplastic AgentsAntioxidantsGlycoside Hydrolase InhibitorsHypoglycemic AgentsInterleukin-6NF-kappa Balloxan-induced modelantidiabeticantioxidantbioinformaticsChronic arthritischronic marker

Identifiers

PMID40985107
PMCPMC12536780

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.